Search hospitals > Quebec > GREENFIELD PARK
CISSS de la Monteregie-Centre
Claim this profileGREENFIELD PARK, Quebec J4V 2H1
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Crohn's Disease
Conducts research for Prostate Cancer
Conducts research for Lymphoma
36 reported clinical trials
2 medical researchers
Summary
CISSS de la Monteregie-Centre is a medical facility located in GREENFIELD PARK, Quebec. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Crohn's Disease, Prostate Cancer, Lymphoma and other specialties. CISSS de la Monteregie-Centre is involved with conducting 36 clinical trials across 40 conditions. There are 2 research doctors associated with this hospital, such as Pierre Desjardins and Etienne Desilets.Area of expertise
1Lung Cancer
Stage IV
Stage III
MET positive
2Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR negative
Top PIs
Pierre DesjardinsHopital Charles-LeMoyne4 years of reported clinical research
Studies Leukemia
Studies Acute Lymphoblastic Leukemia
2 reported clinical trials
6 drugs studied
Etienne DesiletsCISSS de la Monteregie-Centre6 years of reported clinical research
Studies Biliary Obstruction
Studies Ulcer
2 reported clinical trials
3 drugs studied
Clinical Trials running at CISSS de la Monteregie-Centre
Non-Small Cell Lung Cancer
Lymphoma
Prostate Cancer
Multiple Myeloma
Ulcerative Colitis
Leukemia
Lymphoid Leukemia
Chronic B-Cell Leukemia
Chronic Lymphocytic Leukemia
Small Cell Lymphoma
Pembrolizumab vs. Pembrolizumab + Sacituzumab Govitecan
for Non-Small Cell Lung Cancer
This trial compares pembrolizumab alone and in combination with sacituzumab govitecan in adults with advanced lung cancer who have high levels of a certain protein. Pembrolizumab boosts the immune system to fight cancer, while sacituzumab govitecan targets and kills cancer cells. Pembrolizumab has been used as a standard treatment for a type of lung cancer, showing improved survival rates compared to other treatments.
Recruiting2 awards Phase 34 criteria
Telisotuzumab Vedotin vs. Docetaxel
for Non-Small Cell Lung Cancer
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CISSS de la Monteregie-Centre?
CISSS de la Monteregie-Centre is a medical facility located in GREENFIELD PARK, Quebec. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Crohn's Disease, Prostate Cancer, Lymphoma and other specialties. CISSS de la Monteregie-Centre is involved with conducting 36 clinical trials across 40 conditions. There are 2 research doctors associated with this hospital, such as Pierre Desjardins and Etienne Desilets.